http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Escherichia coli 패혈증 환자에 합병된 대칭적 하지 말단 괴사증 1예
남해성,유진홍,권순석,민준기,조현선,박민경,심병주,남유정,이지인,김진수,길욱현,조근종,신완식 대한감염학회 2005 감염과 화학요법 Vol.37 No.6
We have encountered a rare case of symmetrical peripheral gangrene complicating Escherichia coli sepsis in a 47-years-old male. He was successfully treated with antibiotics, anticoagulants, and vasodilator. To our knowledge, this is the first report on symmetrical peripheral gangrene complicating E. coli sepsis in Korea.
( Jee Youn Hong ),( Yoo-min Kim ),( Ji-hee Sung ),( Suk-joo Choi ),( Soo-young Oh ),( Cheong-rae Roh ) 대한산부인과학회 2018 대한산부인과학회 학술대회 Vol.104 No.-
Objective: We aimed to evaluate the effect of magnesium sulfate treatment on the risk of NEC by comparing the rate of NEC between the periods of routine use or non-use of antenatal magnesium sulfate treatment for neuroprotection in preterm deliveries less than 32 weeks of gestation. Methods: This is a retrospective cohort study of neonates who were born between 24+0 and 31+6 weeks of gestations from January 2012 to December 2016. The subjects were classified into three groups (period 1; from January 2012 to December 2013 when antenatal magnesium sulfate treatment for neuroprotection was not used, period 2; from January 2014 to March 2016 when the treatment was routinely used, period 3; from April 2016 to December 2016 when the treatment was abandoned due to its potential risk of NEC. The primary outcome was NEC and neonatal death from NEC. Results: A total of 598 neonates (270 in the period 1, 264 in the period 2, and 64 in the period 3) were included in this study. In the period 2, 160 (60.6%) neonates were exposed to antenatal magnesium sulfate, and among them 124 (77.5%) were used for neuroprotection. In the period 1 and 3, 44 (16.2%) and 9 (14.0%) neonates, respectively, were exposed to antenatal magnesium sulfate and most of them were used for tocolytics or prevention of eclampsia. The rate of NEC was not significantly different among the three periods (23.0% in the period 1, 18.2% in the period 2, and 23.4% in the period 3, P=0.346). The rates of severe NEC (grade II or III), neonatal death due to NEC, and overall neonatal death were not significantly different among the three periods. Conclusion: This study implicates that the change of antenatal magnesium sulfate treatment protocol in preterm neonates was not associated with increased risk of NEC and neonatal death due to NEC. However, further studies are needed to evaluate the long-term effect of this treatment protocol change.